Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. Cancer J Clin. 2023;73(1):17–48.

Article  Google Scholar 

Low G, Huang G, Fu W, Moloo Z, Girgis S. Review of renal cell carcinoma and its common subtypes in radiology. World J Radiol. 2016;8(5).

Dudani S, de Velasco G, Wells JC, Gan CL, Donskov F, Porta C et al. Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association with Survival. JAMA Netw Open. 2021;4(1).

Heng DYC. The next 10 years: challenges for the future and overcoming resistance to targeted therapies for renal cell carcinoma. Can Urol Association J. 2016;10:11–2.

Google Scholar 

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1803–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1103–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1116–27.

Article  CAS  PubMed  Google Scholar 

Mollica V, Di Nunno V, Gatto L, Santoni M, Scarpelli M, Cimadamore A et al. Resistance to systemic agents in renal cell Carcinoma Predict and overcome genomic strategies adopted by Tumor. Cancers. 2019;11(6).

Schaue D, McBride WH. Opportunities and challenges of radiotherapy for treating cancer. Nat Reviews Clin Oncol. 2015;12(9):527–40.

Article  Google Scholar 

Deschavanne PJ, Fertil B. A review of human cell radiosensitivity in vitro. Int J Radiation Oncology*Biology*Physics. 1996;34(1):251–66.

Article  CAS  Google Scholar 

Choi R, Yu JB. Radiation Therapy for Renal Cell Carcinoma. Kidney Cancer. 2019;3(1):1–6.

Article  Google Scholar 

Wu Y, Song Y, Wang R, Wang T. Molecular mechanisms of tumor resistance to radiotherapy. Mol Cancer. 2023;22(1).

Siva S, Louie AV, Warner A, Muacevic A, Gandhidasan S, Ponsky L, et al. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for kidney (IROCK). Cancer. 2017;124(5):934–42.

Article  PubMed  Google Scholar 

Wang H, Mu X, He H, Zhang X-D. Cancer Radiosensitizers Trends Pharmacol Sci. 2018;39(1):24–48.

Article  PubMed  Google Scholar 

Kuwahara Y, Mori M, Kitahara S, Fukumoto M, Ezaki T, Mori S, et al. Targeting of tumor endothelial cells combining 2 Gy/day of X-ray with Everolimus is the effective modality for overcoming clinically relevant radioresistant tumors. Cancer Med. 2014;3(2):310–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Battelli C, Cho DC. mTOR inhibitors in renal cell carcinoma. Therapy. 2011;8(4):359–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Panwar V, Singh A, Bhatt M, Tonk RK, Azizov S, Raza AS et al. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduct Target Therapy. 2023;8(1).

Deutsch E, Le Péchoux C, Faivre L, Rivera S, Tao Y, Pignon JP, et al. Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer. Ann Oncol. 2015;26(6):1223–9.

Article  CAS  PubMed  Google Scholar 

Vapiwala N, Narayan V, Subramanian P, Christodouleas JP, Bekelman JE, Mick R et al. Phase I trial of Everolimus in Combination with Salvage Radiation Therapy (RT) for post-prostatectomy biochemical recurrence (BCR) in prostate Cancer (PC) patients. Int J Radiation Oncology*Biology*Physics. 2016;96(2).

Narayan V, Vapiwala N, Mick R, Subramanian P, Christodouleas JP, Bekelman JE, et al. Phase 1 trial of Everolimus and Radiation Therapy for Salvage Treatment of Biochemical Recurrence in prostate Cancer patients following prostatectomy. Int J Radiation Oncology*Biology*Physics. 2017;97(2):355–61.

Article  CAS  Google Scholar 

Detti B, Francolini G, Becherini C, Olmetto E, Giacomelli I, Scartoni D, et al. Complete response in metastatic renal cell carcinoma after radiotherapy and everolimus: a clinical case and review of the literature. J Chemother. 2016;28(5):432–4.

Article  PubMed  Google Scholar 

Chinnaiyan P, Won M, Wen PY, Rojiani AM, Werner-Wasik M, Shih HA, et al. A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913. Neurooncology. 2018;20(5):666–73.

CAS  Google Scholar 

Ma DJ, Galanis E, Anderson SK, Schiff D, Kaufmann TJ, Peller PJ, et al. A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neurooncology. 2015;17(9):1261–9.

CAS  Google Scholar 

Sarkaria JN, Galanis E, Wu W, Peller PJ, Giannini C, Brown PD, et al. North Central Cancer Treatment Group Phase I Trial N057K of Everolimus (RAD001) and Temozolomide in Combination with Radiation Therapy in patients with newly diagnosed Glioblastoma Multiforme. Int J Radiation Oncology*Biology*Physics. 2011;81(2):468–75.

Article  CAS  Google Scholar 

Carew JS, Espitia CM, Zhao W, Mita MM, Mita AC, Nawrocki ST. Targeting Survivin inhibits renal cell carcinoma progression and enhances the activity of Temsirolimus. Mol Cancer Ther. 2015;14(6):1404–13.

Article  CAS  PubMed  Google Scholar 

Hu S, Fu S, Xu X, Chen L, Xu J, Li B, et al. The mechanism of radiosensitization by YM155, a Novel small molecule inhibitor of Survivin expression, is Associated with DNA damage repair. Cell Physiol Biochem. 2015;37(3):1219–30.

Article  CAS  PubMed  Google Scholar 

Albadari N, Li W. Survivin small molecules inhibitors: recent advances and challenges. Molecules. 2023;28(3).

Rödel F, Hoffmann L Jr, Herrmann M, Noisternig T, Papadopoulos T, et al. Survivin as a Radioresistance Factor, and Prognostic and Therapeutic Target for Radiotherapy in rectal Cancer. Cancer Res. 2005;65(11):4881–7.

Article  PubMed  Google Scholar 

Chakravarti A, Zhai GG, Zhang M, Malhotra R, Latham DE, Delaney MA, et al. Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene. 2004;23(45):7494–506.

Article  CAS  PubMed  Google Scholar 

Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D, et al. Survivin as a Radioresistance factor in pancreatic Cancer. Jpn J Cancer Res. 2005;91(11):1204–9.

Article  Google Scholar 

Yang CT, Li JM, Weng HH, Li YC, Chen HC, Chen MF. Adenovirus-mediated transfer of siRNA against survivin enhances the radiosensitivity of human non-small cell lung cancer cells. Cancer Gene Ther. 2009;17(2):120–30.

Article  CAS  PubMed  Google Scholar 

Chen X, Duan N, Zhang C, Zhang W. Survivin and Tumorigenesis: Molecular mechanisms and therapeutic strategies. J Cancer. 2016;7(3):314–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hagenbuchner J, Kuznetsov AV, Obexer P, Ausserlechner MJ. BIRC5/Survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery. Oncogene. 2012;32(40):4748–57.

Article  PubMed  Google Scholar 

Rivadeneira DB, Caino MC, Seo JH, Angelin A, Wallace DC, Languino LR et al. Survivin promotes oxidative phosphorylation, subcellular mitochondrial repositioning, and tumor cell invasion. Sci Signal. 2015;8(389).

Li F, Aljahdali I, Ling X. Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study? J Experimental Clin Cancer Res. 2019;38(1).

Aoyama Y, Katashima M, Sawamoto T. Lack of differences in the pharmacokinetics of sepantronium bromide (YM155) between US and Japanese patients with advanced solid tumors or non-hodgkin lymphoma. Biopharm Drug Dispos. 2012;34(2):137–40.

Article  PubMed  Google Scholar 

Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022–43.

Article  PubMed Central  Google Scholar 

Kydd J, Jadia R, Velpurisiva P, Gad A, Paliwal S, Rai P. Targeting strategies for the Combination treatment of Cancer using drug Delivery systems. Pharmaceutics. 2017;9(4).

Pal K, Madamsetty VS, Dutta SK, Mukhopadhyay D. Co-delivery of everolimus and vinorelbine via a tumor-targeted liposomal formulation inhibits tumor growth and metastasis in RCC. Int J Nanomed. 2019;145109–23.

Article  CAS  Google Scholar 

Pal K, Madamsetty VS, Dutta SK, Wang E, Angom RS, Mukhopadhyay D. Synchronous inhibition of mTOR and VEGF/NRP1 axis impedes tumor growth and metastasis in renal cancer. Npj Precision Oncol. 2019;3(1).

Karyampudi L, Lamichhane P, Scheid AD, Kalli KR, Shreeder B, Krempski JW, et al. Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Res. 2014;74:(11):2974–85.

Article  CAS  PubMed  PubMed Central